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Agonists of the type 1 sphingosine-1-phosphate (S1P)
receptor inhibit lymphocyte migration, causing their
sequestration in lymphoid tissue. The S1P agonist FTY720
prolongs the survival of organ allografts and blocks T-cell
mediated autoimmune diseases in experimental models;
however, it is a non-selective agonist of four of the five S1P
receptors. In this study female MRL/lpr mice, which develop
an aggressive form of spontaneous autoimmune kidney
disease, were treated with a more selective agonist of the
type 1 receptor (KRP-203) or vehicle at 12 or 16 weeks of age.
Eighty percent of the mice treated at 12 weeks, before the
onset of visible disease, survived to the 24 weeks end point
with decreased tubulointerstitial disease and significantly
fewer infiltrating CD4þ and CD8þ T-cells. Only half of the
control vehicle-treated mice survived. All of the mice treated
at 16 weeks survived with reduced proteinuria. Mice in both
groups had significant reductions in circulating lymphocytes.
Mice receiving KRP-203 for 8–12 weeks had significant
reductions in T-cells and consequently less adenopathy.
Ex vivo treatment of lymphocytes from MRL/lpr mice with
KRP-203 enhanced their apoptosis. Our study indicates that
KRP-203 attenuates kidney injury in MRL/lpr mice, in part, by
reducing T-cell infiltrates.
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Systemic lupus erythematosus is a chronic autoimmune
disease that causes tissue injury in a T-cell-dependent
manner. Lupus nephritis is a leading cause of morbidity
and mortality in systemic lupus erythematosus, and is
characterized by proliferative glomerulonephritis, tubuloin-
terstitial disease, and renal vasculitis. The homing of
activated T cells to the kidney in lupus nephritis is thought
to occur in response to deposition and local production of
immune complexes with complement activation and genera-
tion of other proinflammatory mediators.1,2 Current ther-
apeutic agents, primarily steroids and cyclophosphamide,
target T cells via nonspecific inhibition of activation or
proliferation. Their use, however, has been associated with
significant morbidity.3,4 An alternative approach is to block
recruitment and prevent accumulation of lymphocytes with-
in local sites of inflammation.
Agonists of the type 1 sphingosine-1-phosphate (S1P1)
receptor are important new immunosuppressive agents.5 The
S1P1 receptor is present on lymphocytes
6,7 and controls their
migration throughout the body.8,9 S1P is present in blood
and mediates egress of lymphocytes out of secondary
lymphoid organs back into the circulation.9,10 FTY720 was
the first S1P receptor agonist developed,11 and its adminis-
tration resulted in sequestration of peripheral lymphocytes
into secondary lymphoid organs reducing lymphocytic
infiltrates in target organs. FYT720 use prolongs allograft
survival and attenuates autoimmune-mediated injury in both
humans and experimental animals.5,12–16
Unfortunately, FTY720 has been associated with unanti-
cipated side effects in clinical trials, principally bradycardia,
renal fibrosis, and macular edema. These side effects have
been attributed to the nonselective S1P receptor activity of
FTY720.17–19 S1P receptors are a family of G-protein-coupled
receptors. FTY720 is a potent agonist of four out of the five
known S1P receptors, and the S1P3 receptor has been shown
to mediate many of these side effects.17–19 In addition, FY720
has been shown to activate the cardiac G-protein-gated
potassium channels resulting in bradycardia in vivo.20
Lymphocyte egress from lymph nodes is mediated primarily
by the S1P1 receptor.
9,18,19 Therefore, there is reason to
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believe that selective S1P1 receptor agonists would be effective
immunomodulators without the side effects noted with
FYT720.
KRP-203 (2-amino-2-(2-(4-(3-benzyloxyphenylthio)-2-
chlorophenyl)ethyl)-1,3-propanediol hydrochloride) is a
480 Da compound with a molecular structure similar to
FTY720. KRP-203 is selective for S1P1 and S1P4 receptor
subtypes, with no effect on S1P3 receptors.
21 KRP-203
accelerates lymphocyte homing into secondary lymphoid
organs and blocks their egress similar to FTY720.16,21,22 In
rodents, KRP-203 has been effective in preventing rejection of
skin and heart transplants, with reduced lymphocyte
infiltration into these grafts.22,23 In addition, it prevented
autoimmune myocarditis in rats24 and inflammatory liver
disease and colitis in mice.16,21 Importantly, the cardiac and
vision effects seen with FY720 have not been described with
KRP-203.22
In the present study, KRP-203 was tested for efficacy in a
lymphocyte-dependent model of autoimmune nephritis.
Autoimmunity and kidney disease occur spontaneously in
mice homozygous for the lpr mutation in the MRL genetic
background (MRL/lpr). In MRL/lpr mice, lymphocytes
accumulate in the kidney where they mediate tissue damage.
We postulated that KRP-203 treatment would result in
sequestering of pathogenic lymphocytes in lymphoid tissues
and away from target organs, thereby decreasing kidney
injury and improving survival.
RESULTS
MRL mice that received vehicle only had 50% mortality by 24
weeks of age (Figure 1). However, mice in the treatment
group showed no mortality by 24 weeks (P¼ 0.02). Although
there was a clear trend toward improved survival in the
prevention group, this did not reach statistical significance.
This was primarily due to the loss of two mice that died early
in treatment; importantly, there were no further deaths in
this group either as the mice aged. Dermatitis was variably
present, and there was a modest improvement in groups
treated with KRP-203. Mice in all groups had equivalent
weight gains throughout the study.
Histologic analysis
As inflammatory kidney disease is the primary cause of death
in MRL/lpr mice, renal histology was assessed at 24 weeks. As
expected, kidneys from control mice had severe proliferative
glomerulonephritis, chronic tubulointerstitial disease, and
large perivascular infiltrates (Figure 2a, d and g). Consistent
with the model, most glomeruli were hypercellular with
obliteration of capillary loops, focal segmental sclerosis, and
occasional fibrocellular crescents. Immunofluorescent anti-
body staining for C3 and immunoglobulin G (IgG) showed
the typical pattern with diffuse global staining of mesangium
and capillary loops. There was interstitial fibrosis with diffuse
infiltration of mononuclear cells, tubulitis, and focal tubular
atrophy. Large and small vessels were also surrounded by
large mononuclear cell infiltrates. Immunofluorescence
staining showed that mononuclear infiltrates consisted
mostly of CD4þ or CD8þ T cells, with fewer CD11bþ
monocytes/neutrophils and CD138þ plasma cells (data not
shown).
Mice in the prevention group had reduced histopathology
scores. There were lower glomerular cellularity scores
(P¼ 0.06), and, unlike vehicle-treated controls, none of the
sections analyzed contained glomerular crescents (Table 1).
There was no difference in the degree or distribution of
complement or immunoglobulin staining. However, there
was significantly less tubulointerstitial disease (Table 2) with
preservation of tubular architecture (Figure 2e). Although
there was an overall trend toward less vasculitis (P¼ 0.29),
there was substantial intragroup variability between mice.
There was an eightfold reduction in periglomerular CD4þ
and CD8þ T cells and there were also fewer T cells in the
interstitium. CD11bþ and CD138þ cells were present in
numbers equivalent to kidneys from control mice (data not
shown).
Mice in the treatment group had intermediate histo-
pathology scores. Although there was a trend toward
decreases in glomerular cellularity, the proportion of
glomeruli with crescents, tubulointerstitial disease and the
size of perivascular infiltrates (Tables 1 and 2), none of these
differences achieved statistical significance. Immunofluores-
cence revealed no difference in complement or immuno-
globulin staining, but there were 50% fewer CD4þ and
CD8þ T cells around glomeruli and within the interstitium.
Renal function
Urine protein excretion increased in all mice from 8 to 16
weeks of age. In the treatment group, therapy was associated
with a significant reduction in proteinuria at 20 weeks of age
compared to controls (0.36±0.03 mg/kg/day vs 0.55±0.07
mg/kg/day, respectively; Po0.05). In the prevention group,
half the mice had a marked reduction in urinary protein
excretion, but others did not (mean 0.42±0.09 mg/kg/day).
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Figure 1 | KRP-203 Prolongs survival of MRL/lpr mice.
Kaplan–Meyer curves showing survival of mice treated with
vehicle alone (squares) or KRP-203 6 mg/kg per dose three times
per week starting at either 12 weeks (circles) or 16 weeks of age
(triangles). Numbers of mice surviving to 24 weeks are shown in
parentheses. P-value (treatment vs vehicle)¼ 0.02; P-value
(prevention vs vehicle) 40.05.
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Serum creatinine measurements at 24 weeks showed
equivalent levels in all three treatment groups: control
0.34 mg/100 ml±0.02, prevention 0.38 mg/100 ml±0.02,
and treatment 0.40 mg/100 ml±0.07.
Autoantibodies
All mice had elevated anti-double-stranded DNA antibody
titers compared to pooled serum from nonautoimmune
mice. There was a modest reduction in anti-double-stranded
DNA antibody titers in treated mice and the effect seemed
to correlate with duration of therapy (Figure 3). This
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Figure 2 | Mice treated with KRP-203 have less inflammatory glomerulonephritis and reduced interstitial and perivascular
infiltrates. Representative micrographs of 4-mm PAS-stained sections from paraffin-embedded tissue harvested from mice at 24 weeks of
age. (a–c) Original magnification  400. Glomeruli from mice treated with vehicle alone had more sclerosis, crescents, and periglomerular
infiltrates (a), whereas glomeruli from mice in the prevention (b) or treatment (c) groups had less proliferative lesions with fewer
periglomerular cells. (d–f) Original magnification  200. Cortex from mice treated with vehicle only had large inflammatory infiltrates with
tubular atrophy and loss of normal architecture (d). Cortex from mice in the prevention (e) and treatment (f) groups had more preserved
architecture and reduction in interstitial infiltrates. (g–i) Original magnification  100. Bridging renal vessels from mice treated with vehicle
alone had large circumferential infiltrates that extended into the cortical interstitium (g), whereas equivalent vessels from mice in the
prevention (e) and treatment (f) groups had smaller and irregularly distributed infiltrates.
Table 1 | Glomerular histology scores
Vehicle
(n=6)
Prevention
(n=8)
Treatment
(n=9)
Hypercellularity 2.25±0.19 1.00±0.29* 1.80±0.15
Crescents 13±9.4% 0±0% 8.3±6.8%
C3 staining 1.85±0.16 1.94±0.20 2.08±0.17
IgG staining 1.15±0.13 1.07±0.06 1.15±0.17
CD4+ cells/glomerulus 12.2±3.6 1.5±0.3** 6.8±1.1
CD8+ cells/glomerulus 5.7±1.5 0.8±0.1** 3.8±1.1
IgG, immunoglobulin.
*P-value (prevention vs vehicle) o0.05;
**P-valueo0.01.
Table 2 | Interstitial histology scores
Vehicle
(n=6)
Prevention
(n=8)
Treatment
(n=9)
Vasculitis 3.0±0.00 1.67±0.54 1.75±0.59
Tubulointerstitial disease 3.0±0.00 0.5±0.20* 0.8±0.15
CD4+ cells/hpf 21.3±4.0 6.6±0.8* 11.6±1.3
CD8+ cells/hpf 20.1±1.5 4.7±0.9* 9.5±2.3w
hpf, high-powered field.
*P-value (prevention vs vehicle)o0.05,
wP-value (treatment vs vehicle)o0.05.
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Figure 3 | Duration of treatment-dependent decrease in anti-
double-stranded DNA titers. Absorbance at 450 nm shown from
ELISA using 1:400 dilutions of serum from mice treated with
vehicle alone or KRP-203 for 8 or 12 weeks. Values represent the
means of 8–10 mice per group and bars reflect the standard error.
*P-value o0.05.
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corresponded to less than a fourfold reduction in end point
titers. There were no detectable differences in isotype-specific
titers (data not shown).
Leukocyte analysis
At 24 weeks, there was a significant decrease in both
peripheral lymphocytes (sixfold) and monocytes (fivefold)
in both the prevention and treatment groups compared to
controls (Figure 4). There were no significant differences in
other leukocyte subsets or in the level of anemia. Mice in all
three groups had equivalent platelet counts in the low normal
range (0.3–0.7 million per ml).
All mice had subjective adenopathy at 12 weeks of age, and
this was observed to increase in mice from all three groups up
to 16 weeks. After 8–12 weeks of therapy in the treatment and
prevention groups, respectively, there were decreases in
lymph node size and splenocyte weight compared to control
mice (Figure 5). At 24 weeks, there were 70% fewer lymph
node cells in mice from the treatment group. This was due to
reductions in all T-cell subsets (Table 3), but the greatest
difference was the fourfold decrease in the CD4CD8 T-cell
population in the lymph nodes (Po0.0001). The effect of
KRP-203 therapy on reduced lymphocyte numbers was even
more pronounced in mice from the prevention group. There
were fivefold decreases in CD4þ and CD8þ T cells and 12-
fold decreases in CD4CD8 T cells in the lymph nodes of
mice from the prevention group. There was no difference in
the numbers of CD4þCD25þ T cells between groups. There
were similar reductions in B cells and neutrophils in the
lymph nodes of mice in the prevention and treatment groups,
but no difference in a numbers of CD11bþ cells (data not
shown). Similar findings were found in the spleen.
To assess potential mechanisms for the reduced lympha-
denopathy seen in MRL/lpr mice treated with KRP-203,
lymphocyte survival in ex vivo cultures was assessed after
treatment with increasing doses of KRP-203 or vehicle
control. Lymphocytes were isolated from axillary lymph
nodes of young female MRL/lpr mice at 10 weeks of age.
Nodes are moderately enlarged in mice at this age, and 90%
of lymph node cells are T cells with 5–10% CD4þ , 5–10%
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Figure 4 | Mice treated with KRP-203 have reduced numbers
of circulating leukocytes. Absolute numbers of total white blood
cells (wbc), polymorphonuclear cells (polys), lymphocytes
(lymphs), and monocytes were measured from EDTA-treated
whole blood at 24 weeks. Values are means of samples from five
mice per group and bars reflect the standard error. *P-value
o0.05; **P-value p0.005.
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Figure 5 | KRP-203 reduces splenomegaly and
lymphadenopathy in MRL/lpr mice. Spleen and lymph node
(LN) weights measured at time of harvesting, at 24 weeks or at
time of death. Values are means of samples from 9 to 10 mice and
bars reflect standard error. *P-value o0.05.
Table 3 | Lymphocyte numbers in lymph node
Vehicle (n=5) Prevention (n=8) Treatment (n=9)
LN CD4+ 29.2±8.5 6.3±2.3* 17.8±6.5
LN CD8+ 8.2±2.0 2.5±0.9** 5.1±2.1
LN CD4CD8 130.3±16.9 10.8±4.5*** 30.0±4.4w
LN, lymph node.
Absolute number of cells per node ( 106).
*P-valueo0.001;
**P-value (prevention vs vehicle)o0.05;
***P-valueo0.0001;
wP-valueo0.0001.
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Figure 6 | KRP-203 enhances apoptosis of lymphocytes from
MRL/lpr mice. (a) Histograms of cells stained for Annexin V-FITC
after 24 h incubation with vehicle or increasing concentrations of
KRP-203. Histogram of unstained cells included as a negative
control. Markers indicate positive cells and percent positive cells
are shown in each figure. Data are representative of three
separate experiments. (b) Annexin V-FITC staining of T-cell subsets
after gating on either CD3þ , CD4þ , or CD8þ populations. Lymph
node cells were treated with 0.5mm KRP-203 for 8 h before staining.
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CD8þ , and 70–80% CD4CD8 cells. After 24 h unstimu-
lated in media with serum, 80% of cells were viable by Trypan
blue exclusion or propidium iodide staining. Apoptosis was
assessed by flow cytometry after immunostaining with
Annexin V (Figure 6a). Treatment with KRP-203 revealed a
dose-dependent increase in the proportion of cells staining
positive for Annexin V. Using 10 mM KRP-203, a time course
experiment revealed that 50% of cells were Annexin V
positive at 4 h and nearly all cells were positive by 8 h. Only
20% of untreated cells or cells treated with dimethyl sulfoxide
were Annexin V positive at 8 or 24 h. To determine whether
there were any differences in KRP-203-induced apoptosis in
specific T-cell populations, lymph node cells were exposed to
drug for 8 h. The percentage of Annexin V-positive cells was
similar in both the CD4þ and CD8þ subsets as compared to
the entire CD3þ population (Figure 6b).
DISCUSSION
The present study shows that KRP-203 is effective in
ameliorating chronic inflammatory nephritis in the MRL/
lpr mouse. An 8-week course of therapy starting after the
mice show signs of systemic disease and renal involvement
resulted in less proteinuria, reduced CD8þ cell infiltrates,
and prolonged survival. Further benefit was seen with a
longer duration of therapy starting earlier in the course of
disease. Mice treated for 12 weeks had even fewer circulating
lymphocytes, reduced CD4þ and CD8þ cell infiltrates in the
kidney, and less tubulointerstitial disease.
These results are consistent with prior reports on the use
of FTY720 in the MRL/lpr model.25,26 Daily oral dosing with
FTY720 at 1 mg/kg per dose starting at 16 weeks of age and
lasting 2 weeks led to prolonged survival, although renal
function and kidney histopathology were not assessed. In
total, 9 of 10 treated mice survived 38 weeks, compared to
only 50% survival in untreated mice.25 In another study, oral
dosing with 2 mg/kg per dose three times weekly starting at
16 weeks of age and continuing until 10 month of age was
compared to vehicle alone. Mice receiving FTY720 had
prolonged survival, reduced anti-double-stranded DNA
antibody titers, and reduced IgG staining in glomeruli of
kidneys.26
This study adds to the evidence that S1P receptor agonists
can inhibit disease in MRL/lpr mice. There were reduced
lymphocyte infiltrates in the kidneys of KRP-203-treated
mice: 8 weeks of therapy resulted in fewer CD8þ T cells in
the kidney, and 12 weeks of therapy resulted in reductions in
both CD4þ and CD8þ T cells, suggesting that this effect was
dependent on the duration of therapy. In addition, the
decreased inflammation in the prevention group was
associated with reduced tubulointerstitial disease. Similar to
Okazaki et al.,26 KRP-203 therapy led to reductions in anti-
double-stranded DNA antibody titers. Unlike Okazaki et al.,
we found no differences in glomerular staining for IgG or
complement. However, the reduced T-cell response in KRP-
203-treated mice was associated with reduced proteinuria
even without affecting the degree of IgG or C3 deposition.
Baseline body weights, proteinuria measurements, and
gross examination for adenopathy immediately after rando-
mization revealed no differences between the groups. Twenty-
four weeks was chosen as the time point for censuring the
survival analysis, due to an expected 50% mortality in control
group. As early mortality in MRL/lpr mice is primarily due to
renal failure,2 death of the sickest mice in the control group
may have reduced the power to detect differences in serum
creatinine and glomerular injury scores. Despite this,
statistically significant differences in several measurements
of disease severity were identified.
One important aspect of this study is the long duration of
therapy, as opposed to the short courses described in most
previous studies of KRP-203. Studies in rats looking at
cardiovascular, hepatic, and renal effects of FTY720 used
doses up to 5 mg/kg/day for 21 days.27 With activation by
FTY720, S1P receptors are internalized and degraded, thereby
resulting in a cell that loses responsiveness to gradients of S1P
expression for chemotaxis.28 Initial agonist effects can be
mediated by G-protein activation, but with receptor down-
regulation these effects should be short lived. Therefore, the
effects of long-term therapy with S1P agonists are likely to be
the result of a loss of S1P receptor signaling. It is not known
whether KRP-203 also downregulates S1P1 after binding.
However, this study showed that there were no obvious
effects on growth or vitality after a 3-month course of
therapy.
The long-term exposure to KRP-203 was associated with
lymphopenia as well as reduced lymphocyte numbers in the
spleen and lymph nodes. Lymphopenia has been seen in
other studies with S1P agonists and is expected due to their
effect on blocking egress from lymphoid organs. However,
despite initial progressive adenopathy with KRP-203, there
was ultimately a reduction in spleen and lymph node weights
as well as a decrease in the absolute number of lymphocytes
in these organs. The reduction was dependent on the
duration of therapy, and involved all T-cell subsets, including
CD4CD8 T cells, which specifically survive in the MRL/lpr
mice because of their intrinsic defect in Fas-mediated
apoptosis.29 The mechanism responsible for lymphocyte
depletion with long-term therapy is unclear, although
enhanced apoptosis via a Fas-independent pathway is a
likely possibility.
An apoptotic effect of S1p agonists on MRL/lpr lympho-
cytes has been described previously.25,26 FTY720 has been
reported to promote apoptosis in vitro, although the
occurrence of this effect in vivo has been greatly debated.5
Both KRP-203 and FTY720 are derivatives of sphingosine, a
metabolite in phospholipid metabolism. Sphingosine and its
parent molecule ceramide have both been found to promote
apoptosis via intracellular signaling.30,31 FTY720 requires
phosphorylation in vivo for effect, and the responsible
enzyme is sphingosine kinase type 2.32 It is unclear if
FTY720 or phosphorylated FTY720 serves as a substrate for
other enzymes such as S1P phosphorylase or ceramide
synthase that act on S1P and sphingosine, respectively, to
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generate ceramide. KRP-203 also requires phosphorylation to
function,23 and it is assumed that this occurs in vivo by type 2
sphingosine kinase. Potential metabolites of FTY720 and
KRP-203 could act directly as a second messenger to promote
apoptosis, or alternatively they could indirectly act by
modulating intracellular levels of sphingolipids. Further-
more, sphingosine and ceramide act downstream of Fas
signaling,30 and so T cells from Fas-deficient MRL/lpr mice
could be especially sensitive to S1P agonist induced
apoptosis. The largest decrease in peripheral T cells was
within the CD4 CD8 cell subset; although receptor
expression on this cell population has not been confirmed,
in vitro KRP-203 appeared to effect all T-cell populations
uniformly.
Alternatively, lymphocytes may die of neglect in the
absence of persistent antigenic exposure. Previous studies
have shown that FTY720 treatment results in the accumula-
tion of macrophages in lymph nodes.33 Although reduced
circulating monocytes were seen in KRP-203-treated mice,
monocyte numbers within lymphoid tissue were not altered.
It is unclear from the present study whether these monocytes
are activated or not. If the antigen-presenting cells in the
lymphoid tissue of KPR-203 mice are not sufficiently
activated, T cells sequestered in nodes may be deprived of
requisite costimulatory signals and thus have a heightened
susceptibility to apoptotic death. However, apoptosis would
have to occur in a Fas-independent manner.
Other potential explanations for lymphocyte depletion in
lymphoid organs of KRP-203-treated mice seem less likely.
Although polymorphonuclear cell infiltration of lymphoid
organs has been reported in MRL/lpr mice treated with a 2
weeks course of FTY720,25 lymph nodes from mice after
long-term KRP-203 therapy were not grossly necrotic, and
these nodes contained fewer polys than nodes from control
animals. There was no evidence of lymphocyte egress from
lymphoid tissues back into the blood to explain the decreased
adenopathy. Therefore, apoptosis seems to be the most likely
mechanism.
Due to the widespread distribution of S1P receptors,
multiple cell types have been shown to respond to S1P
agonists. In addition to effects on lymphocytes, drug effects
on other cells could contribute to attenuation of disease in
lupus or lupus-like diseases. In the current study, therapy
with KRP-203 resulted in decreases in blood monocytes as
well as lymphocytes. This could be an indirect effect due to
changes in T-cell activation, or more likely a direct effect of
KRP-203 on monocytes. Receptor expression has been
detected on human monocytes and mouse macrophages,
and exogenous S1P also mediates activation and chemotaxis
of monocytes/macrophages.33,34 In the kidney, rat mesangial
cells express S1P2, S1P3, and to a lesser extent S1P1 and
S1P5.
35,36 S1P binding to S1P2 and S1P3 are required for
platelet-derived growth factor-induced mesangial cell pro-
liferation.36 Treatment of mesangial cells with S1P agonists
in vitro upregulates the activation of SMADs and the
expression of collagen IV, CTGF, and TIM1.17 Although
typically this would lead to increased fibrosis, use of S1P
agonists in an in vivo glomerulosclerosis model showed
attenuation of disease.37 Peters et al. treated animals after
inducing a form of glomerular injury where lymphocyte
infiltration is not typically seen, suggesting that attenuation
of disease was due to loss of S1P signaling in mesangial cells,
likely from receptor downregulation. Although renal en-
dothelial cells have not been examined, other types of
vascular endothelial cells have been reported to express S1P1,
S1P2, and S1P3.
38 Endothelial cells respond to S1P agonists
with colocalization of adhesion molecules in tight junc-
tions.33 These proteins control leukocyte migration across the
endothelial barrier,12 perhaps contributing to reduced hom-
ing of lymphocytes from the blood into local sites of
inflammation. The receptor subtypes responsible for these
cellular responses are being elucidated, but the selectivity of
KRP-203 should minimize nonlymphocyte effects.
In conclusion, treatment with KRP-203 improved survival
and reduced proteinuria in MRL/lpr mice. Earlier, more
prolonged therapy was associated with reduced tubulointer-
stitial disease and fewer T-cell infiltrates in the kidneys of
these mice. There is also a marked reduction in adenopathy
and T-cell numbers in the spleen and lymph node, likely due
to induction of Fas-independent apoptosis. This study
supports the hypothesis that selective S1P1 agonists
may benefit patients with lupus nephritis and other chronic
cell-mediated autoimmune diseases.
MATERIALS AND METHODS
Mice
MRL/MpJ-Tnfrsf6lpr mice (Jackson Laboratories, Bar Harbor, ME,
USA) were maintained in our animal colony on standard mouse chow.
Only female mice were used in this study, as the disease phenotype is
more severe in females. The study was approved by the University of
Texas Health Science Center Animal Welfare Committee.
Experimental design
KRP-203 was obtained from Kyorin Pharmaceutical Co. Ltd (Tokyo,
Japan) and reconstituted in 0.5% methylcellulose (Sigma, St Louis,
MO, USA) at 0.8 mg/ml. Methylcellulose was used as the vehicle
control. Female mice were randomly assigned to one of three groups
at 12 weeks of age. Mice in the prevention group received KRP-203
at 6 mg/kg per dose three times per week by gavage from 12 weeks of
age until 24 weeks. Mice in the treatment group were dosed similarly
but starting at 16 weeks of age. Mice in the control group received
vehicle only by gavage three times per week starting at 12 weeks of
age. Mice were monitored daily for signs of drug toxicity or disease
exacerbations. Weights were obtained twice monthly and drug
dosages were adjusted accordingly.
Histologic analysis
Kidney tissue was fixed in phosphate-buffered saline 4% formalin,
dehydrated and embedded in paraffin. Sections (4mm) were stained
with periodic acid Schiff. Glomerular injury was graded in a blinded
manner as follows, with a minimum of 20 glomeruli scored per
animal: percentage of glomeruli containing cellular crescents,
percentage of glomeruli with sclerosis involving 425% of the
glomerular tuft, and degree of hypercellularity (0–3 scale).
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Tubulointerstitial disease was graded on a 0–3 scale as follows, with
10 high-power fields (HPF) scored per animal: 0, no cellular
infiltrates with back to back tubules, no evidence of fibrosis; 1, 0 to 5
cells per HPF and minimal fibrosis; 2,5 to 10 cells per HPF with
moderate fibrosis; and 3, 410 cells per HPF with marked fibrosis.
Immunostaining
OCT-embedded snap-frozen 4 mm sections of kidneys were used for
direct staining with C3 (MP Biomedicals, Solon, OH, USA) and
IgG-specific antibodies (Zymed, South San Francisco, CA, USA).
Control staining was also performed using matched isotypes or IgG
(data not shown). Staining was scored on a relative scale of 0–3 by
two blinded reviewers for at least 10 glomeruli per mouse. Two-step
indirect staining was performed for CD8 and CD4 using rat primary
antibodies 53–6.7 and RM4-5, respectively, (BD Pharmigen, San
Jose, CA, USA) with a FITC-conjugated donkey anti-rat secondary
antibody (Jackson Immunoresearch, West Grove, PA, USA).
Quantitation of staining was graded based on the number of
positive cells per glomerulus or per HPF for tubular infiltrates, with
a minimum of 10 glomeruli or HPF per mouse examined.
Renal function
At 24 h, urine collections were obtained from mice every 4 weeks
and immediately before histologic analysis. Urinary protein
concentration was determined by bicinchoninic acid assay (Pierce,
Rockford, IL, USA) and normalized for body weight. Blood was
obtained by cardiac puncture and serum was collected after allowing
blood to clot at 37 1C for 1 h. Serum creatinine was determined
using HPLC.39
Leukocyte analysis
Blood was obtained by cardiac puncture at time of histologic
analysis and placed in tubes containing EDTA. Complete blood cell
counts were performed at MD Anderson Cancer Center veterinary
core facility. Splenocytes and axillary lymph node cells were
prepared from mechanical dissociation through 70-mm filters.
Erythrocytes were eliminated via hypo-osmolar lysis. Leukocytes
were washed and stained using directly conjugated antibodies and
assessed by flow cytometry using the FACS Caliber (BD
Biosciences). Antibodies were obtained from eBiosciences: rat
anti-mouse CD4 (clone GK1.5), rat anti-mouse CD8 (53–6.7),
hamster anti-mouse CD3 (145-2c11), rat anti-mouse CD11b (M1/
70), rat anti-mouse B220 (RA3-6B2), and rat anti-mouse CD138
(281-2).
Measurement of antibodies
Serum levels of antibodies reactive to double-stranded DNA were
measured by enzyme-linked immunosorbent assay, as described
previously.40
Apoptosis assay
Lymphocytes were isolated from axillary lymph nodes of young 10-
to 12-week-old female MRL/lpr mice by mechanical dissociation
and washing in sterile Hank’s balanced salt solution. Cells (1 106)
were plated in 1 ml complete RPMI medium with 10% fetal bovine
serum in 24-well tissue culture dishes and incubated at 37 1C and
5% CO2. A stock solution of 10 mM KRP-203 was made in dimethyl
sulfoxide and dilutions were made into RPMI. Dimethyl sulfoxide at
the appropriate dilution was used as a negative control. Annexin V
staining was performed using the apoptosis detection kit (BD
Pharmingen) and cells were analyzed by flow cytometry. Histograms
were generated using WinMDI software, version 2.9 (Scripps,
San Diego, CA, USA). For T-cell subset analysis, two-color staining
was performed using antibodies for CD3, CD4, or CD8 (BD
Pharmingen).
Statistics
Analyses performed using Microsoft Excel and GraphPad Prism
software. Survival data were tested by Kaplan–Meyer analysis with
significance determined by the log-rank test. Kruskal–Wallis test was
used to compare other parameters.
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